Section edited by Paolo A. Ascierto
This section aims to provide a focal point for research that highlights combination therapies, where two or more medications or therapies are strategically combined to improve the treatment of cancer, chronic infections, transplantation and potentially other complex and multi-factorial diseases.
Increasingly detailed understanding of the molecular basis driving complex disease has led to the identifications of new agents that target specific pathways. In some cases treatment of appropriately selected patients has led to striking clinical response, however both primary and secondary resistance mechanisms limited the success of many of these agents. It has become clear that combining or sequencing treatment modalities may en to enrich the communication between basic biological and immunological sciences and the clinical investigation arena.
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells
Takashi Shingu, et al
Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
Jenny E Hernandez-Davies, et al
What’s new in melanoma? Combination!
Paolo A Ascierto, Francesco M Marincola and Michael B Atkins
Annual Journal Metrics
56 days to first decision for reviewed manuscripts only
51 days to first decision for all manuscripts
104 days from submission to acceptance
10 days from acceptance to publication
2,714 Altmetric mentions